The neuropathic pain: An overview of the current treatment and future therapeutic approaches

Eugenio Cavalli, Santa Mammana, Ferdinando Nicoletti, Placido Bramanti, Emanuela Mazzon, Eugenio Cavalli, Santa Mammana, Ferdinando Nicoletti, Placido Bramanti, Emanuela Mazzon

Abstract

Neuropathic pain is characterized by abnormal hypersensitivity to stimuli (hyperalgesia) and nociceptive responses to non-noxious stimuli (allodynia). The conditions and the pathophysiological states that determine the onset of neuropathic pain are heterogeneous, such as metabolic disorders, neuropathy caused by viral infections, and autoimmune diseases affecting the central nervous system (CNS). Neuropathic pain in the general population is estimated to have a prevalence ranging between 3% and 17%. Most of the available treatments for neuropathic pain have moderate efficacy and present side effects that limit their use; therefore, other therapeutic approaches are needed for patients. In this article, the current standard of care treatment, the emerging pharmacological approaches from the completed phase III clinical trials, and the preclinical studies on novel promising therapeutic options will be reviewed.

Keywords: animal models; neuropathic pain; phase III clinical trials; therapy.

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Jensen TS, Baron R, Haanpää M, et al. (2011) A new definition of neuropathic pain. Pain 152: 2204–2205.
    1. Colloca L, Ludman T, Bouhassira D, et al. (2017) Neuropathic pain. Nature Reviews Disease Primers 3: 17002.
    1. IASP (2017) Available at:
    1. Van Hecke O, Austin SK, Khan RA, et al. (2014) Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain 155(4): 654–662.
    1. Finnerup NB, Attal N, Haroutounian S, et al. (2015) Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. The Lancet Neurology 14(2): 162–173.
    1. Electronic Medicines Compendium (eMC). Available at: (accessed 23 November 2018).
    1. Vadivelu N, Kai A, Maslin B, et al. (2015) Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Therapeutics and Clinical Risk Management 11: 95–105.
    1. Attal N. (2018) Pharmacological treatments of neuropathic pain: The latest recommendations. Revue Neurologique 175: 46–40.
    1. Lefaucheur J-P, André-Obadia N, Antal A, et al. (2014) Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology 125(11): 2150–2206.
    1. Attal N, Ayache SS, Ciampi De, Andrade D, et al. (2016) Repetitive transcranial magnetic stimulation and transcranial direct-current stimulation in neuropathic pain due to radiculopathy. Pain 157(6): 1224–1231.
    1. Zhang TC, Janik JJ, Grill WM. (2014) Mechanisms and models of spinal cord stimulation for the treatment of neuropathic pain. Brain Research 1569: 19–31.
    1. De Vos CC, Rajan V, Steenbergen W, et al. (2009) Effect and safety of spinal cord stimulation for treatment of chronic pain caused by diabetic neuropathy. Journal of Diabetes and Its Complications 23(1): 40–45.
    1. Dones I, Levi V. (2018) Spinal cord stimulation for neuropathic pain: Current trends and future applications. Brain Sciences 8(8): 138.
    1. De Vos CC, Bom MJ, Vanneste S, et al. (2014) Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy. Neuromodulation: Journal of the International Neuromodulation Society 17(2): 152–159.
    1. Thomson SJ, Tavakkolizadeh M, Love-Jones S, et al. (2018) Effects of rate on analgesia in kilohertz frequency spinal cord stimulation: Results of the PROCO randomized controlled trial. Neuromodulation: Journal of the International Neuromodulation Society 21(1): 67–76.
    1. Al-Kaisy A, Palmisani S, Pang D, et al. (2018) Prospective, randomized, sham-control, double blind, crossover trial of subthreshold spinal cord stimulation at various kilohertz frequencies in subjects suffering from failed back surgery syndrome (SCS Frequency Study). Neuromodulation: Journal of the International Neuromodulation Society 21(5): 457–465.
    1. Van Beek M, Geurts JW, Slangen R, et al. (2018) Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: Five-year follow-up of a prospective two-center clinical trial. Diabetes Care 41(1): 32–38.
    1. Demartini C, Greco R, Zanaboni AM, et al. (2018) Antagonism of transient receptor potential ankyrin type-1 channels as a potential target for the treatment of trigeminal neuropathic pain: Study in an animal model. International Journal of Molecular Sciences 19: E3320.
    1. Lin J-P, Chen C-Q, Huang L-E, et al. (2018) Dexmedetomidine attenuates neuropathic pain by inhibiting P2X7R expression and ERK phosphorylation in rats. Experimental Neurobiology 27(4): 267.
    1. Afshari K, Dehdashtian A, Haddadi N-S, et al. (2018) Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: Introduction of an alternative therapy. Spinal Cord 56(11): 1032–1041.
    1. Vieira G, Cavalli J, Gonçalves ECD, et al. (2017) Effects of simvastatin beyond dyslipidemia: Exploring its antinociceptive action in an animal model of complex regional pain syndrome-type I. Frontiers in Pharmacology 8: 584.
    1. Marcondes Sari MH, Zborowski VA, Ferreira LM, et al. (2018) Enhanced pharmacological actions of p,p’ -methoxyl-diphenyl diselenide-loaded polymeric nanocapsules in a mouse model of neuropathic pain: Behavioral and molecular insights. Journal of Trace Elements in Medicine and Biology: Organ of the Society for Minerals and Trace Elements (GMS) 46: 17–25.
    1. Chung E, Yoon TG, Kim S, et al. (2017) Intravenous administration of substance p attenuates mechanical allodynia following nerve injury by regulating neuropathic pain-related factors. Biomolecules & Therapeutics 25(3): 259–265.
    1. Xie H-T, Xia Z-Y, Pan X, et al. (2018) Puerarin ameliorates allodynia and hyperalgesia in rats with peripheral nerve injury. Neural Regeneration Research 13(7): 1263.
    1. Qin B, Luo N, Li Y, et al. (2018) Protective effect of gastrodin on peripheral neuropathy induced by anti-tumor treatment with vincristine in rat models. Drug and Chemical Toxicology. Epub ahead of print 17 December. DOI: 10.1080/01480545.2018.1547739.
    1. Araújo-Filho HG, Pereira EWM, Rezende MM, et al. (2017) D-limonene exhibits superior antihyperalgesic effects in a β -cyclodextrin-complexed form in chronic musculoskeletal pain reducing Fos protein expression on spinal cord in mice. Neuroscience 358: 158–169.
    1. Kandhare AD, Mukherjee AA, Bodhankar SL. (2017) Neuroprotective effect of Azadirachta Indica standardized extract in partial sciatic nerve injury in rats: Evidence from anti-inflammatory, antioxidant and anti-apoptotic studies. EXCLI Journal 16: 546–565.
    1. Jones M, Wen J, Selvaraj P, et al. (2018) Therapeutic effect of the substrate-selective COX-2 inhibitor IMMA in the animal model of chronic constriction injury. Frontiers in Pharmacology 9: 1481.
    1. Berrocoso E, Rey-Brea R, Fernández-Arévalo M, et al. (2017) Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days. Nanomedicine: Nanotechnology, Biology, and Medicine 13(8): 2623–2632.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する